Pfizer Inc. $PFE Shares Sold by L.M. Kohn & Company

L.M. Kohn & Company lowered its stake in Pfizer Inc. (NYSE:PFE) by 7.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,216 shares of the biopharmaceutical company’s stock after selling 2,708 shares during the quarter. L.M. Kohn & Company’s holdings in Pfizer were worth $829,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the 1st quarter valued at about $27,000. Curio Wealth LLC lifted its holdings in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in Pfizer in the 1st quarter valued at about $28,000. North Capital Inc. acquired a new stake in Pfizer in the 1st quarter valued at about $28,000. Finally, Harbor Asset Planning Inc. acquired a new stake in Pfizer in the 2nd quarter valued at about $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. Morgan Stanley cut their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.13.

Pfizer Price Performance

NYSE PFE opened at $24.53 on Wednesday. The stock’s 50-day moving average price is $24.84 and its two-hundred day moving average price is $24.23. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $139.44 billion, a PE ratio of 13.05, a PEG ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.17.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.